Pharmaceutical - Markets & Marketing, Nephrology and Hepatology


Popular Filters

US nephrologists view hyperphosphatemia treatment

US nephrologists view hyperphosphatemia treatment


Surveyed nephrologists report awareness of the US Food and Drug Administration's approval of Vifor Fresenius…

AmgenFreseniusGlaxoSmithKlineLa Jolla PharmaceuticalMarkets & MarketingNephrology and HepatologyOPKO HealthPharmaceuticalRayaldeeSensiparUSAvelcalcetideVelphoroVenoferVifor Pharma

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022

Chronic kidney disease drug market forecast to reach $11.7 billion in 2022


After an initial decline driven by generic and biosimilar competition in the G7 (USA, Japan, France,…

AbbVieAmgenAstellas PharmaAstraZenecaGlobalKyowa Hakko KirinMarkets & MarketingNephrology and HepatologyPharmaceuticalRegpararoxadustatSensiparvelcalcetide

Chronic kidney disease market to witness slight decline by 2017

Chronic kidney disease market to witness slight decline by 2017


The value of the chronic kidney disease market could drop 2.5% between 2012 and 2017 due to the loss…

EuropeFinancialGenzymeMarkets & MarketingNephrology and HepatologyPharmaceuticalRenagelRenvelaUSAZemplar Capsules

Alfa Wassermann and Norgine's Targaxan gets first European launch, in UK


Following recent European Union approval (The Pharma Letter December 9, 2012), Netherlands-based Norgine…

Alfa WassermannEuropeMarkets & MarketingNephrology and HepatologyNorginePharmaceuticalTargaxanXifaxan

Japan launches for Lotriga and Argamate


Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

Takeda and Affymax in supply deal for Omontys injection with US Renal Care


Japan's largest drugmaker Takeda Pharmaceuticals (TYO: 4502) and Affymax (Nasdaq: AFFY) have said that…

AffymaxMarkets & MarketingNephrology and HepatologyNorth AmericaOmontysPharmaceuticalTakeda Pharmaceuticals

Astellas debuts Kiklin capsules, for hyperphosphatemia, in Japan


Japanese drug major Astellas Pharma (TYO: 4503) yesterday launched Kiklin capsules 250mg (bixalomar)…

Asia-PacificAstellas PharmaKiklinMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku

Pharma scrambling to expand gout treatment market


Joint pain caused by gout may be on its way out, as the ever-expanding market encourages the discovery…

Anti-Arthritics/RheumaticsMarkets & MarketingNephrology and HepatologyPharmaceuticalResearch

BTG debuts Voraxaze in the USA


The US subsidiary of the UK-based BTG (LSE: BGC) yesterday announced the launch of Voraxaze (glucarpidase)…

ASD HealthcareBTGMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalVoraxaze

Astellas and Sanwa to co-promote kidney disease drugs in Japan


Japanese drug major Astellas Pharma (TYO: 4503) yesterday revealed that it has linked up with fellow…

ArgamateAsia-PacificAstellas PharmabixalomerMarkets & MarketingNephrology and HepatologyPharmaceuticalSanwa Kagaku




Back to top